Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Drops By 57.7%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 1,303 shares, a drop of 57.7% from the January 15th total of 3,079 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 8,921 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 8,921 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the company’s shares are short sold.

Global X Genomics & Biotechnology ETF Stock Performance

NASDAQ:GNOM traded up $0.29 on Friday, reaching $45.70. The company’s stock had a trading volume of 2,586 shares, compared to its average volume of 9,353. Global X Genomics & Biotechnology ETF has a 1-year low of $27.20 and a 1-year high of $51.42. The business’s 50-day moving average price is $47.26 and its two-hundred day moving average price is $42.62. The firm has a market cap of $49.81 million, a PE ratio of -19.53 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently declared a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were paid a $0.5912 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a yield of 259.0%. Global X Genomics & Biotechnology ETF’s payout ratio is presently -26.50%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC raised its position in Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after acquiring an additional 10,308 shares in the last quarter. Insight Advisors LLC PA lifted its stake in Global X Genomics & Biotechnology ETF by 47.9% in the 2nd quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock valued at $503,000 after purchasing an additional 19,319 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Global X Genomics & Biotechnology ETF by 8.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock valued at $756,000 after purchasing an additional 6,708 shares during the last quarter. Atria Investments Inc grew its holdings in Global X Genomics & Biotechnology ETF by 12.6% during the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after purchasing an additional 2,073 shares during the period. Finally, Creative Financial Designs Inc. ADV increased its position in Global X Genomics & Biotechnology ETF by 86.7% during the second quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock worth $188,000 after buying an additional 10,358 shares during the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.